• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas

    4/24/25 8:00:00 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AKYA alert in real time by email

    MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company®, and Enable Medicine, a real-world data company providing AI-ready patient, cellular and molecular data, today announced a groundbreaking collaboration to deliver the largest commercially available single-cell spatial proteomics atlas to the research and clinical community.

    Enable Medicine's Pan-Cancer Atlas is a unique multi-modal dataset built using Akoya's PhenoCycler®-Fusion (PCF) platform and includes the PhenoCode™ Discovery IO60 panel as its foundational data. The Enable Atlas comprises over 100 million single cells, spanning 8,500+ samples and 15+ cancer types, with rich cellular features, including up to 60 protein biomarkers, accompanying H&E images and spatial transcriptomics measurements, and comprehensive clinical metadata.

    The Enable Atlas is curated, standardized, and commercially licensable. It provides immediate value to biopharma researchers and AI model developers seeking to accelerate biomarker discovery, drug development, and translational insights. It is a special mechanism for new and existing PhenoCycler-Fusion customers to further power their experiments by integrating their data with the Enable Atlas.

    "The Enable Atlas is a catalytic resource for our customers," said Niro Ramachandran, Chief Business Officer at Akoya Biosciences. "Biopharma customers now have the potential to generate new hypotheses from existing data, increase the statistical power of their studies, and identify novel cellular phenotypes at a scale never before possible."

    Built for scale. Designed for discovery.

    The Enable Atlas's spatial proteomics layer was generated using Akoya's PhenoCycler-Fusion, the industry's fastest and most scalable spatial biology platform, and included the ultrahigh-plex IO60 panel, capturing broad biological diversity across tissue types.

    Enable Medicine's software platform hosts the dataset and makes it easily explorable, allowing users to filter and subset by biomarker expression, tissue type, clinical metadata, and more. These analytical and annotation capabilities make the Atlas a powerful tool for biomarker discovery, comparative analysis, and statistical validation in discovery and translational research.

    "Our strategy to map disease and provide insightful biological data requires technologies that scale. PhenoCycler-Fusion and IO60 made this possible — this combination uniquely powered the generation of our large, high-resolution, and biologically rich proteomic dataset," said Aaron Mayer, Chief Scientific Officer at Enable Medicine. "This level of multiplexing, throughput, and consistency was essential to create a resource that's not only comprehensive but immediately impactful in therapeutic, diagnostic, and scientific research settings."

    Key features of the Enable Pan-Cancer Atlas:

    • Unmatched scale and depth: Over 100 million spatially profiled single cells
    • High-dimensional data: up to 60 protein markers with spatial context, H&E, and spatial transcriptomics data on select samples
    • Diverse sample coverage: 8,500+ samples across 15+ cancer indications and normal tissues
    • Rich metadata: Clinical context to power translational insights
    • Immediate usability: Licensable and structured for downstream analysis

    Meet Us at AACR 2025

    The Spatial Atlas will be showcased at the upcoming American Association for Cancer Research (AACR) Annual Meeting, offering attendees a first look at this new spatial proteomics resource.

    Location: Akoya Booth #3045 | April 27 | 4:30–5:00 PM

    A live demonstration of the Atlas will be available during the scheduled session. Members of the Akoya and Enable Medicine teams will be on-site to discuss how the dataset can be applied to translational research, biomarker discovery, and drug development programs. For more information, visit https://sb.akoyabio.com/aacr2025.

    About Akoya Biosciences

    As The Spatial Biology Company®, Akoya Biosciences' mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit www.akoyabio.com.

    About Enable Medicine

    Enable Medicine is a real-world data company unlocking new insights into human disease via integrated patient, cellular and molecular information. The company offers AI-ready biological data, data management tools and data analysis services to fuel the development of large multimodal foundational models, diagnostics and drug development. Enable Medicine's data solutions support science spanning the discovery of novel therapeutic targets to assist with better clinical trial design. To learn more about Enable, visit www.enablemedicine.com.

    Akoya Forward-Looking Statements

    This press release contains forward-looking statements that are based on Akoya management's beliefs and assumptions and on information currently available to Akoya management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements concerning the capabilities and potential of Akoya's products and services, its collaboration with Enable Medicine, its future performance and its plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents Akoya files with the Securities and Exchange Commission from time to time. The reader is cautioned that forward-looking statements are based on a combination of facts and factors currently known by Akoya and Akoya's projections of the future, about which Akoya cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Akoya's views as of the date hereof. Akoya undertakes no obligation to update any forward-looking statements for any reason, except as required by law.

    Investor Contact:

    Priyam Shah

    [email protected]

    Media Contact:

    Ritu Mihani

    [email protected]

    Enable Medicine Business Development Contact:

    Jess Werlin

    [email protected]



    Primary Logo

    Get the next $AKYA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AKYA

    DatePrice TargetRatingAnalyst
    11/15/2024$7.00 → $5.00Buy → Hold
    Craig Hallum
    8/6/2024Overweight → Equal-Weight
    Morgan Stanley
    8/6/2024Buy → Neutral
    BTIG Research
    8/6/2024Overweight → Neutral
    JP Morgan
    6/21/2024$7.50Buy
    Craig Hallum
    12/14/2023Neutral
    Guggenheim
    7/5/2023$18.00Overweight
    JP Morgan
    2/2/2023$14.00Buy
    UBS
    More analyst ratings

    $AKYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Akoya Biosciences downgraded by Craig Hallum with a new price target

      Craig Hallum downgraded Akoya Biosciences from Buy to Hold and set a new price target of $5.00 from $7.00 previously

      11/15/24 8:33:16 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences downgraded by Morgan Stanley

      Morgan Stanley downgraded Akoya Biosciences from Overweight to Equal-Weight

      8/6/24 12:17:30 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences downgraded by BTIG Research

      BTIG Research downgraded Akoya Biosciences from Buy to Neutral

      8/6/24 6:28:51 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Clinical Officer Bamford Pascal covered exercise/tax liability with 670 shares, decreasing direct ownership by 0.32% to 205,738 units (SEC Form 4)

      4 - Akoya Biosciences, Inc. (0001711933) (Issuer)

      6/2/25 5:52:39 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • CFO Ek John Frederick covered exercise/tax liability with 16,432 shares, decreasing direct ownership by 6% to 248,202 units (SEC Form 4)

      4 - Akoya Biosciences, Inc. (0001711933) (Issuer)

      4/3/25 5:14:37 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President and CEO Mckelligon Brian covered exercise/tax liability with 7,550 shares, decreasing direct ownership by 2% to 420,126 units (SEC Form 4)

      4 - Akoya Biosciences, Inc. (0001711933) (Issuer)

      3/25/25 6:34:07 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

      RINCON, Puerto Rico, May 23, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement regarding the Company's Post-Effective Amendment to its S-4 registration statement and Akoya Biosciences' ("Akoya") (NASDAQ:AKYA) disclosure of an unsolicited all-cash offer at $1.40-per-share. "Quanterix's amended merger terms (the "Amended Merger Agreement"), structured to avoid a shareholder vote, already commit the company to pay $20 million in cash alongside 8.4 million newly issued shares in its misguided pursuit of Akoya. On May 20, 20

      5/23/25 2:21:00 PM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences Reports First Quarter 2025 Financial Results

      MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. "Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals," said Brian McKelligon, CEO of Akoya Biosciences. "As we

      5/12/25 4:05:00 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders

      It is Deeply Disturbing, in Kent Lake's View, that the Company's Amended Agreement to Merge with Akoya Deprives Quanterix Shareholders of Ability to Vote on the Transaction Believes Quanterix's Maneuvers Further Demonstrate the Need for New Directors with Real Credibility and Accountability to Shareholders – And Will Press on With Nominations of Three Highly Qualified Board Candidates Kent Lake PR LLC ("Kent Lake"), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement regarding the Company's announcement of an amended merger agreement (the "Amended Merger Agreement") relat

      4/30/25 8:00:00 AM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    SEC Filings

    See more
    • SEC Form DEFM14A filed by Akoya BioSciences Inc.

      DEFM14A - Akoya Biosciences, Inc. (0001711933) (Filer)

      6/16/25 11:03:33 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 425 filed by Akoya BioSciences Inc.

      425 - Akoya Biosciences, Inc. (0001711933) (Subject)

      6/4/25 4:01:16 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya BioSciences Inc. filed SEC Form 8-K: Other Events

      8-K - Akoya Biosciences, Inc. (0001711933) (Filer)

      6/2/25 4:05:19 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Leadership Updates

    Live Leadership Updates

    See more
    • Akoya Biosciences Announces Leadership Transition

      Joe Driscoll to Retire After More than Four Successful Years as Chief Financial Officer Johnny Ek Appointed as new Chief Financial Officer MARLBOROUGH, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that Chief Financial Officer Joe Driscoll is retiring from his position, effective March 20, 2023. Johnny Ek has been appointed as the company's new Chief Financial Officer, effective immediately. Mr. Driscoll will continue to serve as a consultant of the company as Akoya executes a seamless transition between the two leaders. Mr. Driscoll joined Akoya in April 2019 and has overseen the company's financ

      3/20/23 4:00:00 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel

      MARLBOROUGH, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced the appointment of Jennifer Kamocsay as General Counsel. Ms. Kamocsay will oversee all company legal activities and provide strategic guidance and corporate governance oversight. "We are excited to welcome Jennifer to our leadership team," said Brian McKelligon, Chief Executive Officer of Akoya. "Her deep legal expertise and insight will be invaluable as we continue to advance our spatial biology platform and establish additional partnerships to support discovery, translational, and clinical markets." Ms. Kamocsay most recently served as Gen

      2/28/23 8:00:00 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences Announces Ehab A. El-Gabry, MD, as Chief Medical Officer

      MARLBOROUGH, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced the appointment of Dr. Ehab A. El-Gabry as the company's Chief Medical Officer (CMO). In this newly created position, Dr. El-Gabry will lead Akoya's strategy in advancing the use of its spatial phenotyping solutions in the clinical setting. Dr. El-Gabry brings a wealth of experiences that are critical to the company's vision of advancing spatial phenotyping in precision medicine and cancer care. He is a board-certified pathologist who served as the Senior Medical Director for Roche Tissue Diagnostics Personalized Health Care Solutions (PHCS). As the

      4/19/22 8:05:00 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Financials

    Live finance-specific insights

    See more
    • Akoya Biosciences Reports First Quarter 2025 Financial Results

      MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. "Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals," said Brian McKelligon, CEO of Akoya Biosciences. "As we

      5/12/25 4:05:00 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

      MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2024. "Akoya navigated a challenging 2024 in the life science tools market, which was constrained by subdued capital equipment purchases, by successfully strengthening gross margins, reducing operating expenses and advancing our companion diagnostics programs throughout the year. We remain optimistic about the long-term growth outlook of Akoya's leading spatial biology solutions," said Brian McKelligon, CEO of Akoya. "In 2024, Akoya achieved multiple milestones, i

      3/17/25 4:00:00 PM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers

      Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across translational, academic and pharma applications Expects to generate approximately $40 million of annual cost synergies by the end of 2026 with path to positive free cash flow generation in 2026 Combined cash position of approximately $175 million with no expected debt at closing to pursue future growth initiatives Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ

      1/10/25 7:00:00 AM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Akoya BioSciences Inc.

      SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)

      11/4/24 7:39:24 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Akoya BioSciences Inc.

      SC 13G - Akoya Biosciences, Inc. (0001711933) (Subject)

      8/28/24 10:45:17 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Akoya BioSciences Inc. (Amendment)

      SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)

      2/14/24 4:09:03 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials